Jazz Pharmaceuticals (JAZZ) Gross Profit (2010 - 2026)

Jazz Pharmaceuticals has reported Gross Profit for 17 years, with the latest figure at $934.8 million in Q1 2026.

• For the quarter ending Q1 2026, Gross Profit rose 17.85% year-over-year to $934.8 million; the trailing twelve-month figure through Mar 2026 stood at $3.9 billion (up 8.2% YoY), and the FY2025 full-year result was $3.8 billion, up 3.89% from the prior year.
• Gross Profit for Q1 2026 stood at $934.8 million, down from $1.0 billion in the prior quarter.
• The five-year high for Gross Profit was $1.0 billion in Q4 2025, with the low at $698.4 million in Q1 2022.
• Average Gross Profit over 5 years is $872.9 million, with a median of $870.0 million recorded in 2023.
• Year-over-year, Gross Profit gained 27.83% in 2022 and declined 1.65% in 2025.
• Tracing JAZZ's Gross Profit over 5 years: stood at $804.8 million in 2022, then advanced by 12.42% to $904.7 million in 2023, then rose by 6.05% to $959.5 million in 2024, then grew by 8.85% to $1.0 billion in 2025, then fell by 10.49% to $934.8 million in 2026.
• The last three Gross Profit figures came in at $934.8 million (Q1 2026), $1.0 billion (Q4 2025), and $997.2 million (Q3 2025), per Business Quant data.

Peer Comparison